touchPODCAST

The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES

Listen to three leading experts explore mRNA vaccine platforms for respiratory viruses, including their design, clinical application and future prospects.

The experts

• Dr Anna Blakney – University of British Columbia, Vancouver, BC, Canada
• Prof. Dr. med. Oliver Cornely – University of Cologne, Germany
• Prof. Ann R Falsey – University of Rochester School of Medicine, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Moderna. This activity is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchinfectiousdiseasesime.org/mrna-vaccine-platform-respiratory-viral-infections

The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections

touchEXPERT OPINIONS for touchRESPIRATORY

Listen to three leading experts explore mRNA vaccine platforms for respiratory viruses, including their design, clinical application and future prospects.

The experts

• Dr Anna Blakney – University of British Columbia, Vancouver, BC, Canada
• Prof. Dr. med. Oliver Cornely – University of Cologne, Germany
• Prof. Ann R Falsey – University of Rochester School of Medicine, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Moderna. This activity is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchrespiratoryime.org/mrna-vaccine-platform-respiratory-viral-infections/

Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations

touchIN CONVERSATION for touchRESPIRATORY

Listen to Dr Yasushi Goto (National Cancer Center Hospital, Tokyo, Japan) in conversation with Professor Paul Paik (Memorial Sloan Kettering Cancer Center, New York, USA) on how to optimize the management of patients with NSCLC and MET alterations. 

In Part 1 they respond to questions from the oncology and respiratory clinical communities on:

• Biomarker testing in advanced NSCLC
• Identifying patients with METex14 skipping mutations
• Targeting METex14 skipping mutations

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from the healthcare Business of Merck KGaA, Darmstadt, Germany, and is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchrespiratoryime.org/met-alterations-nsclc-management/

Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations

touchIN CONVERSATION for touchONCOLOGY

Listen to Dr Yasushi Goto (National Cancer Center Hospital, Tokyo, Japan) in conversation with Professor Paul Paik (Memorial Sloan Kettering Cancer Center, New York, USA) on how to optimize the management of patients with NSCLC and MET alterations. 

In Part 1 they respond to questions from the oncology and respiratory clinical communities on:

• Biomarker testing in advanced NSCLC
• Identifying patients with METex14 skipping mutations
• Targeting METex14 skipping mutations

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from the healthcare Business of Merck KGaA, Darmstadt, Germany, and is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/met-alterations-nsclc-management/

Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer

touchEXPERT OPINIONS for touchONCOLOGY

An oncologist, a nurse and a urologist share their insights on the risks and benefits of androgen deprivation therapy, the barriers to equitable care and how to improve treatment adherence for patients with prostate cancer.

 The experts

• Dr Tanya Dorff, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
• Ms Brenda Martone, Northwestern Medicine, Chicago, IL, USA
• Dr Stephen Freedland, Cedars-Sinai, Los Angeles, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Pfizer Inc. and is jointly provided by USF Health and touchIME.

For further information visit: touchoncology.com

Optimizing IOL selection Focus on IOL calculations in “difficult” eyes

touchIN CONVERSATION for touchOPHTHALMOLOGY

In this activity, listen to ophthalmology experts, Prof. Sumit Garg and Dr Karolinne Rocha, respond to questions from the ophthalmology community on IOL selection in cataract patients, focusing on the preoperative assessment of ocular health, optimizing IOL calculations, and the impact of previous surgeries on lens selection.

This touchPODCAST is for healthcare professionals only. 

This activity is funded by an independent medical education grant from Alcon Vision, LLC and Johnson & Johnson Surgical Vision, Inc. and is jointly provided by USF Health and touchIME.

For further information visit our website: touchOPHTHALMOLOGY

Anti-CGRP antibody preventive treatment of migraine: Practical management

touchCLINICAL PERSPECTIVES for touchNEUROLOGY

Listen to two case-based interviews with migraine specialists focusing on preventive treatment of migraine with anti-CGRP antibodies. In the first, a clinical expert shares his perspectives on treatment failure in patients with migraine, providing insights and guidance, while the second discussion considers different clinical scenarios to focus on practical management.

The experts:

• Prof. Christian Lampl, Konventhospital Barmherzige Brüder, Linz, Austria
• Dr Simy Parikh, Thomas Jefferson University Hospital, Philadelphia, PA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from Eli Lilly and Company Limited. This medical education is provided by touchIME.

For further information visit our website:  
https://touchneurology.com/the-role-of-anti-CGRP-antibodies-in-migraine-prevention/ 

The complement system in NMOSD and MG: A target for therapeutic benefit?

touchPANEL DISCUSSION for touchOPHTHALMOLOGY

Listen to a panel of leading experts discuss  the evidence for complement involvement in the pathogenesis of neuromyelitis optica spectrum disorder and myasthenia gravis, review the markers of complement activation, and highlight the implications of the latest data for complement therapeutics for practice.

The experts

• Prof. Said Beydoun, Keck School of Medicine of USC, Los Angeles, CA, USA
• Prof. Heinz Wiendl, University Hospital Münster, Münster, Germany
• Dr Pushpa Narayanaswami, Beth Israel Deaconess Medical Center, Boston, MA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Alexion Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

To view this activity in full and to access the downloadable materials please visit: touchOPHTHALMOLOGY

The complement system in NMOSD and MG: A target for therapeutic benefit?

touchPANEL DISCUSSION for touchIMMUNOLOGY

Listen to a panel of leading experts discuss  the evidence for complement involvement in the pathogenesis of neuromyelitis optica spectrum disorder and myasthenia gravis, review the markers of complement activation, and highlight the implications of the latest data for complement therapeutics for practice.

The experts

• Prof. Said Beydoun, Keck School of Medicine of USC, Los Angeles, CA, USA
• Prof. Heinz Wiendl, University Hospital Münster, Münster, Germany
• Dr Pushpa Narayanaswami, Beth Israel Deaconess Medical Center, Boston, MA, USA

This touchPODCAST is for HCPs only.

An independent medical education grant from Alexion Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchIMMUNOLOGY

The complement system in NMOSD and MG: A target for therapeutic benefit

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to a panel of leading experts discuss  the evidence for complement involvement in the pathogenesis of neuromyelitis optica spectrum disorder and myasthenia gravis, review the markers of complement activation, and highlight the implications of the latest data for complement therapeutics for practice.

The experts

• Prof. Said Beydoun, Keck School of Medicine of USC, Los Angeles, CA, USA
• Prof. Heinz Wiendl, University Hospital Münster, Münster, Germany
• Dr Pushpa Narayanaswami, Beth Israel Deaconess Medical Center, Boston, MA, USA

This touchPODCAST is for HCPs only.

An independent medical education grant from Alexion Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchNEUROLOGY